Trial Profile

A multicentre, randomized, double-blind, placebo-controlled clinical study to investigate the use of IntelGenx's Montelukast VersaFilm® for the treatment of Parkinson's Disease ("PD")

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Apr 2024 According to an Intelgenx media release, trial is being conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx's previously announced research collaboration with Per Svenningsson, MD, PhD, who is the study's Lead Principal Investigator.
08 Apr 2024 Status changed from planning to recruiting, according to an IntelGenx Corp.media release.
08 Apr 2024 According to an IntelGenx Corp.media release, company announced that first patient has been dosed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com